Johnson & Johnson (JNJ) said Friday that it has submitted for Emergency Use Listing to the World Health Organization or WHO for the investigational single-dose Janssen COVID-19 vaccine candidate.
The company said that the Emergency Use Listing process expedites access to products in many countries around the world and is also a prerequisite to supply vaccines to the new COVAX Facility, a global mechanism for pooled procurement and distribution of COVID-19 vaccines in 190 participating countries, including 92 lower-income countries.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com